查看文章

Background and Aim:  Per protocol annual liver biopsy represents the gold standard in the assessment of graft fibrosis progression due to recurrent hepatitis C after liver transplantation. Non‐invasive liver fibrosis tests have been proposed as surrogate markers of liver fibrosis in hepatitis C virus (HCV)‐positive immune‐competent patients. No data are available in the literature on the usefulness of non‐invasive liver fibrosis tests in liver transplanted patients with recurrent HCV infection.

Methods:  A total of 102 annual per protocol liver biopsies performed in 51 consecutive HCV‐positive recipients (31 men), with a follow‐up period lasting up to 5 years, were included and evaluated in this study. At each time point, the following non‐invasive liver fibrosis tests were calculated: aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio, age–platelet index, AST to platelet ratio index (APRI), Forns …